54.160.244.62
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Conference Roundup

Aflibercept trial highlights significance of baseline characteristics in DME

A trial evaluating the use of aflibercept 8 mg in patients with diabetic macular edema (DME), found that baseline disease severity may have been greater in patients with shortened dosing intervals, particularly with the 8 mg every 16 weeks dosing regimen. The study observed differences in visual acuity, central retinal thickness,...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-